NASDAQ:FOMX - Menlo Therapeutics Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$2.99
+0.30 (1.20%)
Get New Menlo Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FOMX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FOMX

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Menlo Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $2.99.

This chart shows the closing price for FOMX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Menlo Therapeutics. This rating has held steady since September 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/28/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/26/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/24/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/21/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/20/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/19/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/21/2019HC WainwrightReiterated RatingBuy$10.00 ➝ $11.00High
9/23/2019CowenSet Price TargetBuy$30.00Medium
8/9/2019Bank of AmericaReiterated RatingBuy$11.00High
6/11/2019BarclaysInitiated CoverageOverweight ➝ Overweight$10.00Medium
5/28/2019HC WainwrightSet Price TargetBuy$12.00High
5/7/2019Cantor FitzgeraldReiterated RatingBuy$15.00Low
4/2/2019Cantor FitzgeraldReiterated RatingBuy$15.00High
3/1/2019CowenSet Price TargetBuy$30.00Medium
1/4/2019HC WainwrightSet Price TargetBuy$12.00High
12/12/2018Bank of AmericaInitiated CoverageBuy ➝ Buy$11.00Medium
12/4/2018HC WainwrightSet Price TargetBuy$12.00Medium
11/7/2018CowenSet Price TargetBuy$30.00N/A
10/11/2018Cantor FitzgeraldInitiated CoverageOverweightLow
10/8/2018HC WainwrightSet Price TargetBuy$11.00Medium
9/18/2018HC WainwrightSet Price TargetBuy$11.00High
9/12/2018HC WainwrightReiterated RatingBuy ➝ Buy$12.00 ➝ $14.00High
8/9/2018HC WainwrightSet Price TargetBuy$12.00Low
7/16/2018HC WainwrightReiterated RatingBuy$12.00Low
5/8/2018HC WainwrightSet Price TargetBuy$12.00Low
4/17/2018HC WainwrightSet Price TargetBuy$12.00High
1/5/2018HC WainwrightSet Price TargetBuy$12.00High
12/14/2017GuggenheimReiterated RatingBuy$8.00High
12/5/2017GuggenheimInitiated CoverageBuy ➝ Buy$8.00Medium
11/29/2017HC WainwrightSet Price TargetBuy$12.00Low
8/24/2017HC WainwrightInitiated CoverageBuy ➝ Buy$12.00High
7/19/2017Credit Suisse GroupReiterated RatingBuy$9.00Low
3/28/2017Credit Suisse GroupLower Price TargetOutperform$22.00 ➝ $9.00High
2/15/2017Credit Suisse GroupInitiated CoverageOutperform$22.00N/A
(Data available from 9/19/2016 forward)

News Sentiment Rating

0.30 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/21/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/23/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/22/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/22/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/21/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/21/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/20/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/19/2021

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Menlo Therapeutics logo
Foamix Pharmaceuticals Ltd., a late clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations for dermatological therapy in the United States, France, Denmark, and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline that has completed third pivotal Phase III clinical trial for the treatment of moderate-to-severe acne; and FMX103, which is in Phase III clinical trial for the treatment of moderate-to-severe papulopustular rosacea. The company's product pipeline includes FCD105 and FMX109 for the treatment of moderate-to-severe acne vulgaris; and FMX110 for the treatment of papulopustular rosacea. Foamix Pharmaceuticals Ltd. has development and license agreements with Bayer HealthCare AG; LEO Pharma A/S; Mylan N.V.; and Actavis plc. The company was founded in 2003 and is headquartered in Rehovot, Israel.
Read More

Today's Range

Now: $2.99
Low: $2.99
High: $2.99

50 Day Range

MA: $2.99
Low: $2.99
High: $2.99

52 Week Range

Now: $2.99
Low: $1.97
High: $4.84

Volume

N/A

Average Volume

518,350 shs

Market Capitalization

$184.12 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.66

Frequently Asked Questions

What sell-side analysts currently cover shares of Menlo Therapeutics?

The following Wall Street analysts have issued reports on Menlo Therapeutics in the last year:
View the latest analyst ratings for FOMX.

What is the current price target for Menlo Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Menlo Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Menlo Therapeutics in the next year.
View the latest price targets for FOMX.

What is the current consensus analyst rating for Menlo Therapeutics?

Menlo Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for FOMX.

What other companies compete with Menlo Therapeutics?

How do I contact Menlo Therapeutics' investor relations team?

Menlo Therapeutics' physical mailing address is 2 HOLZMAN ST. WEIZMANN SCIENCE PARK, REHOVOT L3, 76704. The specialty pharmaceutical company's listed phone number is 972-8931-6233 and its investor relations email address is [email protected] The official website for Menlo Therapeutics is www.foamix.com.